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Invasive ductal adenocarcinoma of the pancreas remains an almost univer-
sally lethal disease. Despite strenuous research efforts, the prognosis of
the disease has not improved in the past decades. However, knowledge of
pancreatic tumorigenesis and the identification and characterization of the
precursor lesions that give rise to invasivepancreatic cancerhavedramatically
improved. This, coupledwith the finding that it takes almost two decades for
a pancreatic cell with an initial mutation to develop into a metastatic pancre-
atic cancer provides hope for the early detection of curable pancreatic
neoplasms. We present a review of established precursor lesions of pancre-
atic cancer, includingpancreatic intraepithelial neoplasia, intraductalpapillary
mucinous neoplasms (including intraductal oncocytic papillary neoplasmand
intraductal tubulopapillary neoplasm), and mucinous cystic neoplasm.
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Introduction
Invasive pancreatic ductal adenocarcinoma (PDAC, i.e. pancre-
atic cancer), is the fourth leading cause of cancer-related deaths
in the USA.1 In 2008, an estimated 161,800 world-wide deaths
were attributed to pancreatic cancer in the developed world, and
the mortality rate approaches its incidence (10e12:100,000).2
The 5-year survival rate of pancreatic cancer is a bleak <6%
which is due, at least in part, to the fact that the vast majority of
patients (w80%) are diagnosed with locally advanced or meta-
static disease.1 Chemo- and/or radiation therapies are only
marginally effective, increasing survival by only a few months
for only a subset of patients.3 Therefore, it is crucial that
pancreatic neoplasia be detected earlier, before an invasive
cancer develops, while the disease is still curable.
It is now recognized that invasive pancreatic cancer arises
from histologically well-defined noninvasive precursor lesions.
This, combined with the recent finding that it takes many years
for a pancreatic cell with an initial mutation to progress to
a metastatic cancer, highlights a significant window of opportu-
nity for early detection.4
The first step in developing an early detection test is to identify
curable precursor lesions and to understand their biology.5,6
Herein, we present a review of the literature on four recognized
precursor lesions of pancreatic cancer, beginning with the
microscopic pancreatic intraepithelial neoplasia (PanIN) followed
by the macroscopic intraductal papillary mucinous neoplasm
(IPMN) including intraductal oncocytic papillary neoplasm
(IOPN), then briefly covering intraductal tubulopapillary
neoplasm (ITPN), and fourth a discussion of the mucinous cystic
neoplasm (MCN).7 Finally, recent advances in cyst fluid analysis
and its potential use in diagnosis (for biomarker detection) will be
discussed, highlighting findings that could be of potential benefit
for the detection and treatment of precursors to PDAC.
Pancreatic intraepithelial neoplasiaClinical appearance and morphology of PanINsMicroscopic intraductal lesions believed to be precursors to
invasive pancreatic cancer have been recognized for more than
a century.8 It was only in the past 2e3 decades that molecular
studies helped establish that these small lesions, now called
PanINs, are definitely precursors to PDAC.9e12
Like PDAC itself, PanINs are encountered mostly in the head of
the pancreas and less in the body and/or tail. In one large autopsy
study, the overall prevalence of PanINs was approximately 19%
(Table 1).12 In addition, the prevalence of PanINs has been found
to increase with age; 6.7% of patients aged 50 years, 28% of
patients aged 50e65 and 37% of patients aged65 harbour PanIN
lesions. Cubilla and Fitzgerald reported that PanIN-2 (which they
had designated as intermediate-grade ductal papillary hyper-
plasia) was three times more prevalent in pancreata with an
associated invasive cancer than in those without, and the highest
grade lesions (i.e. PanIN-3) were only found in pancreata with an
associated PDAC.11 Similarly, Andea et al. reported that PanINs
were more common in pancreata harbouring PDAC (82%), than
in pancreata with pancreatitis (60%) and normal pancreata 2011 Elsevier Ltd. All rights reserved.
General characteristics of precursor lesions of pancreatic cancer
PanIN IPMN MCN ITPN
Sex ratio (female:male) 1:1 2:3 20:1 1:1
Predominant age of
diagnosis
Increasing with age 60e70 40e50 56 (mean)
Intrapancreatic location Head>body/tail Head>body/tail Body/tail Head>body>tail
Relation with pancreatic
duct(s)
Occur in small ducts Occur in main and/or
branch ducts
None Occur in dilated ducts
Diagnostic features by
imaging techniques
Chronic pancreatitis-like
changes in very few
patients
Dilated pancreatic
duct, filling defects,
cyst(s)
Cystic mass with thick
walls that compresses/
displaces duct
Resemble pancreatobiliary-
type IPMNs
Macroscopic features Mostly not grossly
visible (<5 mm)
Dilated pancreatic
ducts with abundant
mucin
Well-defined cysts with
thick walls containing
mucin or hemorrhagic
material
Solid nodular masses
within ducts, no mucin
Microscopic features Columnar/papillary
mucinous epithelium,
adjacent parenchymal
atrophy may be present
Flat, micro/grossly
papillary epithelium,
parenchymal atrophy
may be present
Mucin-producing
columnar cells with
associated ovarian-like
stroma
Cribriform or solid with
necrosis
PanIN, pancreatic intraepithelial neoplasia; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; ITPN, intraductal tubulopapillary
neoplasm.
Table 1
MINI-SYMPOSIUM: PANCREATIC PATHOLOGY(16%).9 Thus, PanINs, particularly high-grade PanINs, increase
with age and are associated with PDAC.13
Pancreatic intraepithelial neoplasia occurs in smaller pancre-
atic ducts and are <5 mm in diameter which makes PanINs
generally not grossly detectable. In fact, size is one of the features
used to distinguish PanINs from IPMNs which, by definition, are
usually >1 cm. PanINs are characterized by the replacement of
the normal cuboidal ductal epithelium by columnar mucinous
cells, either flat or papillary, with various degrees of dysplasia.
PanINs are divided in three grades based on the degree of
cytonuclear and architectural atypia (Figure 1).14,15 Typically,
low-grade or PanIN-1A lesions have a flat epithelium consisting
of columnar mucinous cells with basally located round to oval
uniform nuclei (containing supranuclear mucin) which are
perpendicularly oriented to the basement membrane. In contrast
to PanIN-1A, PanIN-1B lesions have a (micro)papillary archi-
tecture. PanIN-2 lesions feature greater architectural complexity,
including early loss of nuclear polarity, pseudostratification and
hyperchromasia (i.e. darker nuclei), all consistent with
intermediate-grade dysplasia. In PanIN-3 lesions (high-grade
dysplasia or carcinoma-in situ), significant cytological atypia is
present and includes complete loss of nuclear polarity, hyper-
chromasia, conspicuous nucleoli and the presence of mitotic
figures (occasional abnormal mitotic figures). Architectural
changes in PanIN-3 lesions include (micro)papillary rather than
flat epithelium, sometimes luminal necrosis, and cribriform
architecture, the phenomenon of so-called Roman bridge
formation between tufts. Of note, PanIN-3 lesions are still
confined within the basement membrane and there is no invasive
growth of the neoplastic epithelial cells.
The clinical significance of a PanIN at the margin of an
otherwise R0 resection for PDAC was recently examined.DIAGNOSTIC HISTOPATHOLOGY 18:1 18In contrast to the negative effect of invasive cancer at a margin,
PanIN, even high-grade PanIN-3 at a margin appears to have no
clinical significance for patients with an invasive cancer.16
PanINs are often surrounded by lobular parenchymal atrophy
(i.e. lobulocentric atrophy) (Figure 1f).17e19 Observations in
humans suggest that PanIN lesions obstruct exocrine outflow in
the ducts and the subsequent release of acinar enzymes to the
parenchyma leads to autodigestion, thus creating localized
pancreatitis-like atrophy. By contrast, observations in genetically
engineered animal models suggest that genetic changes in acinar
cells drive acinar-ductal metaplasia imparting the appearance of
lobulocentric atrophy. Patients with a strong family history of
pancreatic cancer sometimes have multiple PanIN lesions which
produce multifocal lobulo-centric atrophy and radiological
changes similar to those seen in chronic pancreatitis. This
suggests that a specific at-risk population can be screened for the
presence or absence of PanINs by looking for theses changes.19
A number of intraductal lesions should be considered in the
differential diagnosis of PanINs. First, repeated ductal epithelium
injury can lead to the replacement of normal cuboidal cells by
mature stratified or pseudostratified squamous epithelium,
commonly referred to as squamous metaplasia. Squamous
metaplasia is distinguished from PanINs by the direction of
differentiation of the cells, and the absence of significant atypia
in squamous metaplasia. Second, duct inflammation and repair
can produce reactive atypia with enlarged nuclei and nucleoli.
The inflammation helps distinguish reactive atypia from PanINs.
Third, ‘cancerization of ducts’ can occur as invasive cancer
grows from the stroma back into and along previously non-
neoplastic ducts. Two features distinguish PanINs from this
“cancerization.” Cancerization is almost always associated with
an invasive carcinoma in the stroma next to the lesion in 2011 Elsevier Ltd. All rights reserved.
Figure 1 Progression of pancreatic intraepithelial neoplasia (PanIN) lesions. (a) Normal pancreatic duct lined by cuboidal epithelium without atypia.
(b) PanIN-1A lesion featuring flat columnar, mucinous epithelium with basally-oriented nuclei with only minimal cytological atypia. (c) PanIN-2 lesion with
papillary architecture, pseudostratified tall columnar epithelium and moderate architectural and cytological atypia. (d) PanIN-3 lesion with significant
architectural and cytological atypia, i.e. note the cribriform areas and budding off of clusters of cells as well as the enlarged, hyperchromatic nuclei with
loss of polarity. (e) Moderately differentiated invasive pancreatic ductal adenocarcinoma (note the abundant stroma). (f ) Lobulocentric atrophy
surrounding a pancreatic duct with low-grade PanIN.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYquestion, and cancerization is characterized by an abrupt
transition between normal and abnormal epithelium. Finally,
and most challenging, PanINs are sometimes almost impossible
to distinguish from smaller branch-duct IPMNs (see below),
especially the gastric-type. As there is histological overlap,
IPMNs are often multifocal, and histologically tend to have
longer papillae and more abundant mucin production than do
PanINs. PanINs are defined as lesions <5 mm (microscopic) and
IPMNs are generally macroscopically appreciated (>10 mm). We
and others have suggested the term “incipient IPMN” for the
large grey zone between larger PanINs and smaller IPMNs
(i.e. <10 mm).20 The presence of a radiologically detectable
lesion favours the diagnosis of IPMN.Molecular alterations in PanINsPanINs have been extensively studied at the molecular level.21e25
The “PanINgram” is a widely accepted progression model inDIAGNOSTIC HISTOPATHOLOGY 18:1 19which an accumulation of molecular alterations is seen with
increasing grades of dysplasia.26 Although the genetic alterations
in PanINs do not necessarily occur in a specific order, they
eventually lead to uncontrolled cell growth, and the development
of an invasive carcinoma.26 These molecular changes include
DNA mutations, epigenetic modification of the DNA, and
changes in RNA and protein expression.
Activating point mutations of the KRAS2 oncogene, usually of
codons 12 or 13, play a central role in the development of
PanINs. KRAS2 gene mutations have been detected in 36% of
PanIN-1A lesions, 44% of PanIN-1B lesions, and 87% of
PanIN-2/3 lesions in one study; the latter closely approximating
the >90% prevalence of KRAS2 gene mutations observed in
PDAC (Table 2).27,28 The RAS family of proto-oncogenes encode
small GTP-binding proteins that mediate cell-cycle progression
and cell proliferation, differentiation and survival through path-
ways, including the RAF-mitogen-activated protein kinase 2011 Elsevier Ltd. All rights reserved.
Common mutations observed in pancreatic precursor lesions versus PDAC
Type Gene/protein Cellular function PanIN IPMN PDAC
PanIN-1A/B PanIN-2 PanIN-3
Tumour
suppressor
genes
p16/CDKN2A G1/S-transition w30% 55% 71% >50% Methylated 95%
TP53 Cell-cycle arrest Observed Varies greatly 50e75%
SMAD4 TGF-b signalling w30% w50%
p21/CDKN1 G1/S-transition 16% 80%
LKB1/STK11 Cell polarity 25%
Oncogenes KRAS2 MAPK/ERK signalling 36e44% 87% 31e81% >90%
GNAS Signal transduction (Gsa) 66% 0%
a
PIK3CA Cell proliferation/survival 7e10%
BRAF MAPK/ERK signalling Rare 5%
Genome
maintenance
genes
BRCA2 DNA damage repair Observed 7e10%
PanIN, pancreatic intraepithelial neoplasia; IPMN, intraductal papillary mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma; TGF-b, transforming growth
factor b; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; Gsa, G protein a-subunit.
a Non-IPMN-associated PDAC.
Table 2
MINI-SYMPOSIUM: PANCREATIC PATHOLOGY(MAPK), phosphatidylinositol 3-kinase (PI3K)/AKT, and the
Ral-GDS pathway. The importance of KRAS2 gene mutations in
the development of PanINs is highlighted by genetically engi-
neered mouse models in which the expression of a mutant
KrasG12D allele leads to formation of murine PanIN (mPanIN)
lesions which eventually progress to invasive adenocarcinoma.29
Another early event in the development of PanINs is telomere
shortening, which has been observed in >90% of PanIN
lesions.30 Interestingly, shortened telomeres can also be seen in
acinar-to-ductal metaplasia, but only when these latter lesions
are associated with PanIN lesions, suggesting that the neoplastic
epithelium of PanIN lesions may focally grow “back” into
associated acini and replace the acinar epithelium.31
Inactivating mutations in tumour suppressor genes have also
been demonstrated in PanIN lesions. Briefly, the most widely
recognized and earliest of these alterations include inactivation
of the cell-cycle gene p16 (CDKN2), found in w30% of PanIN-
1A/B, 55% of PanIN-2 and 71% of PanIN-3 lesions.32 Inactiva-
tion (through intragenic mutations and loss of heterozygosity
(LOH)) of the TP53 gene occurs in one-half to one-third of
PDACs, and appears to be limited to PanIN-3 lesions, thus
rendering TP53 gene inactivation a late event in tumorigenesis.
The TP53 gene codes for the p53 protein, a transcription factor
involved in cell-cycle control and apoptosis. Another late event
in pancreatic tumorigenesis is the inactivation of the tumour
suppressor gene SMAD4 (DPC4) in approximately one-third of
PanIN-3s and w50% of PDAC cases.33 Inactivation of SMAD4
results in an escape from canonical transforming growth factor
b (TGF-b)-mediated growth inhibition. A number of tumour
suppressor genes are silenced by hypermethylation in PanINs;
for example, Sato et al. found that any of the eight genes
commonly altered in PDAC were aberrantly methylated in 71%
of PanIN-1 lesions, while PanIN-3 lesions harboured significantly
more methylated loci than did the lower grade lesions.34DIAGNOSTIC HISTOPATHOLOGY 18:1 20While some genes are somatically inactivated in PanINs, in
other cases a germline mutation is coupled with a somatic
mutation in the remaining allele. For example, in patients
harbouring a germline BRCA2 gene mutation, LOH at the BRCA2
locus (13q12.3) has been demonstrated in PanIN-3 lesions.
BRCA2 codes for a protein involved in repairing double strand
DNA breaks, and germline mutations in BRCA2 are associated
with an increased risk of breast, ovarian and pancreatic
cancer.35,36
The patterns of protein expression in PanINs have also been
defined by immunolabeling. Typically, the apomucins MUC1,
MUC4 and MUC5AC are expressed in PanINs and immunolab-
eling for specific mucins can help distinguish a large PanIN from
a small intestinal-type IPMN (Table 3).37 Other proteins of
interest overexpressed in PanIN lesions include mesothelin,
a GPI-anchored protein, and prostate stem cell antigen (PSCA).26
Of interest, the aberrant overexpression of the pericentromeric
satellite repeat HSATII in PanIN and PDAC has recently been
reported, and it has been suggested that HSATII is a possible
specific biomarker for the progression of dysplasia.38Intraductal papillary mucinous neoplasmClinical appearance and morphology of IPMNsIPMNs are mucin-producing epithelial lesions in the ductal
system of the pancreas that are, in contrast to PanINs, macro-
scopic lesions. IPMNs arise more often in the head than in the
body or tail of the gland, and IPMNs are slightly more common in
males (w60% of cases) (Table 1). The usual age at which
patients with an IPMN are diagnosed is 60e70 years, and
patients with noninvasive IPMNs tend to be 3e5 years younger
than patients with an IPMN with an associated invasive
carcinoma. Patients with an IPMN can present with nonspecific
symptoms such as abdominal discomfort/pain, back pain, 2011 Elsevier Ltd. All rights reserved.
Apomucin expression patterns in pancreatic precursor lesions
MUC1 MUC2 MUC4 MUC5AC MUC6
Normal duct þ e e e e
PanINs PanIN-1A þ e þ þþþ þ
PanIN-1B þ e þ þþþ þ
PanIN-2 þþ e þþ þþþ þ
PanIN-3 þþþ e þþþ þþþ þ
IPMNs Intestinal e þþ e þþ Weak
Pancreatobiliary þþ e e þþ Some
Gastric e e e þþ e
Oncocytic þ Goblet cells only e Goblet cells only þþ
ITPN Focal e e e þþ
MCN Noninvasive e þ e þþþ e
Invasive þ þ e þþþ e
PanIN, pancreatic intraepithelial neoplasia; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; ITPN, intraductal tubulopapillary
neoplasm.
Table 3
Figure 2 Branch-duct IPMN located in the body of the pancreas where
a single cyst is visible with flat lining. The main pancreatic duct (arrows) is
not involved and is dilated at the level of the IPMN. Note that the cyst wall
is relatively simple without mural nodules.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYnausea, vomiting, anorexia, weight loss and recurrent episodes
of pancreatitis. In some instances patients report having had
symptoms for over 10 years. IPMNs have been reported in
individuals with a family history of pancreatic cancer and in
patients with Peutz-Jeghers syndrome.19,20,39
By far the most important prognosticator in an IPMN is the
presence or absence of an associated invasive carcinoma. The
5-year survival rate for patients with an IPMN with an invasive
carcinoma is 34e62% compared to 77e100% for patients with
an IPMN without an associated invasive carcinoma.40e42 The
“Sendai criteria,” international consensus guidelines developed
at a meeting in Sendai, Japan, provide consensus criteria on
when to clinically monitor and when to resect IPMNs.43,44
Briefly, the criteria advocate surgical resection of all main duct
IPMNs and the resection of branch-duct IPMNs that are symp-
tomatic, >3 cm, harbour a mural nodule, or associated with
significant dilatation of the pancreatic duct. If cytology is positive
for carcinoma, those lesions should also be resected.
Currently, some of the best noninvasive modalities to evaluate
an IPMN include high-resolution computerized tomography
(CT), magnetic resonance imaging (MRI) and magnetic reso-
nance cholangiopancreatography (MRCP). These imaging tech-
niques will generally reveal a pancreatic cyst with ectasia of the
main duct, multiple cysts with dilatation of branch ducts, or
a mixture of these. Endoscopic ultrasonography (EUS) is slightly
more invasive than these other technologies, but provides greater
resolution and can be used for sampling cyst fluid contents by
fine needle aspiration (FNA). The finding of mucin oozing from
a prominent ampulla of Vater (i.e. “fish mouth papilla”) on EUS
is virtually diagnostic of an IPMN.
IPMNs can be divided in three types: main duct, branch duct,
and combined- or mixed-type based on their macroscopic
appearance.45 Main-duct IPMNs usually occur in the head of the
gland with often the presence of copious thick mucin which gives
rise to a (diffusely) dilated main pancreatic duct. Branch-duct
IPMNs involve side branches of the main pancreatic duct, as the
name suggests, and occur mainly in the head and uncinateDIAGNOSTIC HISTOPATHOLOGY 18:1 21process. Branch-duct IPMNs are often multicystic grape-like
structures with thin cyst walls (Figure 2). Mixed-type IPMNs
involve both the main and branch ducts. Both main and branch-
duct IPMNs can be associated with atrophy of the adjacent
pancreatic parenchyma.
IPMNs grossly contain either papillary projections (villous
growth) or flat epithelium (ductectatic pattern) as opposed to the
thin, translucent normal ductal epithelium. Differentiation
between the types of IPMNs is clinically relevant as main duct
and combined-type IPMNs tend to harbour higher grades of
dysplasia and are more likely to be associated with infiltrating
adenocarcinoma than are branch-duct IPMNs. Specifically,
a recent analysis found infiltrating carcinoma associated with
48% of main-duct IPMNs, 42% of combined-type IPMNs and
only 11% of branch-duct IPMNs.46 Pathologists should be aware
that invasive carcinoma can arise focally within an IPMN, and
therefore IPMNs need to be thoroughly sampled histologically. 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYSeveral gross features can be suggestive of invasive adenocarci-
noma in IPMNs. These include irregular heterogeneous thick-
ening of cyst walls, fibrotic foci, and the presence of solid/
gelatinous stromal nodules.
Invasive carcinoma arising in IPMNs have significantly better
survival than primary PDAC not arising in association with an
IPMN, but much of this difference is attributable to the lower
stage at which IPMN-associated carcinomas are diagnosed.47,48
Colloid adenocarcinomas, almost always arise from intestinal-
type IPMNs, have a significantly more favourable outcome
than do tubular adenocarcinomas.47,49
Since IPMNs can be multifocal, surgically resected patients
should be followed after their surgery for metachronous disease.
Microscopically, IPMNs can be classified based on the degree
of cyto-architectural atypia into low-, intermediate- and high-
grade lesions.50 IPMNs can also be classified based on the
direction of differentiation of the neoplastic epithelium into
intestinal-, pancreatobiliary-, gastric-, and oncocytic-types,
although this subtyping is less important clinically than the
presence or absence of an associated invasive carcinoma
(Figure 3).50 The recently recognized intraductal tubulopapillary
neoplasm (ITPN) will be covered separately due to its “novelty.”
Intestinal- and pancreatobiliary-type IPMNs are typically
observed in main-duct IPMNs, while branch-duct IPMNs
typically exhibit gastric-type epithelium. The intestinal-type
IPMN consists of long papillae built up by columnar mucin-
producing cells with cigar-shaped pseudostratified nuclei and
basophilic cytoplasm. Intermediate- to high-grade dysplasia is
usually seen in this type which closely resembles colonic villous
adenomas. Pancreatobiliary-type IPMNs are characterized by
more complex thin papillae with branching, built up by cuboidalFigure 3 Histology of intraductal papillary mucinous neoplasm (IPMN) lesions.
dysplasia. (c) High-grade pancreatobiliary IPMN with cuboidal neoplastic epit
abundant cytoplasm.
DIAGNOSTIC HISTOPATHOLOGY 18:1 22cells containing less mucin and round hyperchromatic nuclei
which thus explains its usual appearance as high-grade
dysplasia. It is less common for gastric-type IPMNs to have
papillary features as they instead are composed of single layers of
flat cells (i.e. almost always a low-grade dysplasia) with basally-
oriented nuclei. As the name suggests, gastric-type IPMNs
resemble gastric-foveolar epithelium; the cytoplasm contents are
abundant and pale coloured and occasional goblet cells may be
appreciated. Oncocytic-type IPMNs, also known as intraductal
oncocytic papillary neoplasms (IOPNs), are composed of cells
with abundant eosinophilic cytoplasm. The architecture of IOPNs
is complex, including arborizing papillae, solid nests, and crib-
riform growth pattern with intraepithelial lumina formation.
The stratified oncocytic neoplastic cells contain abundant
eosinophilic granular cytoplasm with large round (uniform)
nuclei and typically feature high-grade dysplasia. As scattered
goblet cells may also be observed, it might be hard to appreciate
the intraductal nature of this lesion. Because regularly multiple
histological types can be appreciated within an IPMN, the
dominant component should be used to determine its subtype.
The different types of IPMNs have distinct patterns of
apomucin expression that distinguishes them (Table 3). In short,
the intestinal-type typically expresses MUC2 (and transcription
factor CDX2), the pancreatobiliary-type expresses MUC1, the
gastric-type only expresses MUC5AC, and lastly IOPNs express
MUC1 and MUC6.15 In addition, the noninvasive pan-
creatobiliary-type also expresses MUC6 which is virtually absent
in the intestinal- and gastric-type IPMNs.51 The latter suggests
differentiation into a pyloropancreatic tumorigenic lineage rather
than the intestinal MUC2/CDX2 pathway found in intestinal- and
gastic-type IPMNs.51(a) Low-grade gastric-type IPMN. (b) Intestinal-type IPMN with high-grade
helium forming complex papillae. (d) An IOPN composed of cells with
 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYMolecular alterations in IPMNsFigure 4 Histologic feature of a high-grade ITPN with cribriform
architecture and minimal mucin production.A growing body of evidence suggests that an accumulation of
genetic alterations in specific genes drives the progression of
IPMNs to invasive carcinoma. Recently, mutations in the
oncogene GNAS were discovered in 66% of IPMNs.52 The major
gene product of GNAS is the G protein a-subunit (Gsa) which is
a necessary signal transducer between hormonal (amongst other)
receptors and adenylyl cyclase to produce cAMP production;
activating mutations in GNAS are believed to cause continuous
cAMP production, in turn leading to proliferation.53 Mutations in
the GNAS gene appear to be specific for IPMNs as they are not
present in nonIPMN-associated PDACs nor in MCNs and other
cystic neoplasms of the pancreas.52,54 This finding is exciting
because GNAS gene mutations can be detected in cyst fluid,
suggesting that IPMNs could be definitively diagnosed by
analyzing cyst fluid aspirates for GNAS gene mutations (see
below). The most common mutations encountered in IPMNs
are activating KRAS2 gene mutations (up to 80% of cases), with
increasing prevalence from low- to higher-grade IPMNs
(Table 2).52,55e64 Of note, KRAS2 gene mutations are not
a feature of IOPNs.62 p53 overexpression, indicative of an
underlying mutation in the TP53 gene has also been observed in
high-grade IPMNs.59,60,62,65,66 A smaller percentage of IPMNs
harbour LKB1 gene (also known as STK11) mutations. Loss of
heterozygosity at the LKB1 locus (19p13.3) as well as loss of
LKB1 expression has been reported in 25% of IPMNs.39,67 Lkb1 is
a serine threonine kinase upstream of mTOR; germline mutation
of LKB1 is associated with Peutz-Jeghers syndrome, and biallelic
inactivation of LKB1 has been reported in IPMNs that arise in
patients with Peutz-Jeghers syndrome. Up to 10% of IPMNs
harbour mutations in the PIK3CA gene, and the protein product
of PIK3CA, phosphatidylinositol 3-kinase, is also involved
upstream of AKT-mTOR signalling.60,68 Recently, a BRAF muta-
tion was reported in an IOPN.62
Loss of expression of p16 and SMAD4 has been reported in
IPMNs, but SMAD4 inactivation is not as common in IPMNs as it
is in high-grade PanINs.66,69,70 Microsatellite analysis in IPMNs
revealed allelic losses at chromosomes 9p in 62%, and 17p and
18q in both 38%.71 Since these regions harbour the genes p16,
TP53 and SMAD4 this suggests that biallelic inactivation of these
genes is targeted during IPMN progression. Microsatellite anal-
yses and analyses of the patterns of GNAS and KRAS2 gene
mutations have supported the histologic finding of multifocality
of IPMNs.71
Aberrant methylation also occurs widely in IPMNs, more in
invasive carcinomas associated with IPMNs than in noninvasive
lesions.72e74 Specifically, methylation of p16, p73 and APC
(respectively in >50, >50 and 10% of noninvasive IPMNs),
methylation of mismatch repair genes MLH1 and MGMT (20% of
noninvasive IPMNs) and methylation of CLDN5 (33% of low-,
42% of intermediate-, and 62% of high-grade IPMNs) have been
observed.72,73
Oligonucleotide microarray expression analyses have
revealed significantly higher claudin-4, S100A, CXCR4 and
mesothelin expression in IPMNs associated with an invasive
carcinoma than in noninvasive IPMNs.75 Moreover, simulta-
neous overexpression of at least two of these proteins in one
lesion was observed in 73% of invasive carcinomas arising from
IPMNs.DIAGNOSTIC HISTOPATHOLOGY 18:1 23Aberrant expression of microRNAs, a class of noncoding
RNAs with a regulatory translational function of mRNA
transcripts, has been reported in IPMNs. The microRNAs miR-21
and miR-155 have been shown to be expressed in IPMNs at levels
>10-fold compared to those seen in normal ductal cells.76 It has
been speculated that microRNAs might serve as a biomarker for
early pancreatic neoplasia since aberrant expression of these
microRNAs can also be detected in pancreatic juice (see below).
Shortened telomeres have also been reported in IPMNs.30,77
Specifically, 50% of low-grade IPMNs have shortened telomeres,
with average length decreasing with IPMN progression. This
finding suggests that telomere shortening is also an early event in
the IPMN tumorigenesis. Alterations found in cyst fluid associated
with IPMNs will be discussed at the end of this review.ITPN: clinical appearance, morphology and molecular
alterationsITPNs are rare (w3% of pancreatic intraductal neoplasms)
grossly visible intraductal lesions characterized by solid growth
pattern, minimal mucin production, tubulopapillary architecture,
and frequent necrosis. ITPNs are generally large (on average 6
cm) solid nodular masses (Table 1). Microscopically the
neoplastic cells have a cribriform growth pattern with only
occasionally papillae (Figure 4).78 ITPNs are usually not associ-
ated with cyst formation and they do not, by definition, produce
abundant mucin. Most ITPNs have high-grade dysplasia and in
less than half of the cases an associated invasive component is
found.50,79 The rare incidence of the lesion leaves extensive
(prognostic) data unavailable, but 5-year survival is >30%.
ITPNs typically express cytokeratin 7 and 19, underlining their
ductal differentiation, and almost all express MUC1. Apomucin 6
is expressed in roughly 60% of cases but MUC2 and MUC5AC are
not expressed, features that can help distinguish these lesion from
IPMNs (Table 3). Mutations in the KRAS2 and BRAF genes have
not been observed in ITPNs, and aberrant expression of b-catenin
and loss of Smad4 and E-cadherin expression is rare (10%).
However, abnormal expression of p53 and p16 has been observed
more frequently (20% and 54%, respectively).80
As stated before, ITPNs should be differentiated from IPMNs,
especially the pancreatobiliary-type. Apart from the already 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYmentioned absence of copious mucin, less prominent cyst
formation and distinct apomucin labelling (Table 3), ITPNs occur
in younger patients (by a decade) than IPMNs and typically have
more cribriform rather than complex papillary structures.
Mucinous cystic neoplasmClinical appearance and morphology of MCNsMCN can also be a precursor to invasive pancreatic cancer.46
MCNs arise more often in the body or tail of the pancreas than
in the head of the gland, and over 90% of the patients are
females, usually between the ages of 40e50 years (Table 1).81
The median age of diagnosis of MCN with an associated
invasive carcinoma is around 55 years. Patients with MCNs
usually present with nonspecific symptoms such as abdominal
discomfort and the sensation of a mass in the epigastric region.
At the time of diagnosis, about one-third of MCNs have an
associated invasive carcinoma, but this number may drop as
more and more MCNs are being detected in asymptomatic
patients imaged for another indication. Patients with a surgically
resected noninvasive MCN are essentially cured, while the 5-year
survival rate for patients with an MCN with an associated inva-
sive carcinoma is 50e60%.82,83 In contrast to IPMNs, MCNs are
almost always unifocal, and the risk of metachronous disease
after surgery for an MCN is therefore minimal.
MCNs generally form well-circumscribed cystic masses with
thick septa (visible on EUS) (Figure 5). Unilocular tumours have
a smooth glistering internal surface whereas papillary projections
may be present in higher-grade lesions. MCNs with an associated
invasive carcinoma were found to be significantly larger and
more often contain mural nodules than noninvasive MCNs.84
Cyst fluid of MCNs is either mucinous or hemorrhagic in
nature and can have elevated tumour marker levels of carci-
noembryonic antigen (CEA) or cancer antigen 19-9 (CA19-9);
when an associated invasive carcinoma is present the levels of
these tumour markers can be elevated in the plasma as well.85
Histologically, MCNs are composed of mucin-producing
columnar epithelial cells that can have pseudopyloric,
gastric-foveolar, small- or large-intestinal differentiation. By
definition, MCNs also contain a dense ovarian-type stromaFigure 5 A gross zoomed image of a sectioned mucinous cystic neoplasm
(MCN) containing thick septae (arrows) and numerous cystic lesions
containing mucinous nonhaemorrhagic fluid. Note the smooth glistering
surface of the lesion and absence of papillary projections.
DIAGNOSTIC HISTOPATHOLOGY 18:1 24composed of densely packed spindle-shaped cells with elongated
nuclei (Figure 4b). The ovarian-type stroma, together with a lack of
communication of the cystic lesion(s) with the duct system, helps
distinguishMCNs from IPMNs.86 The ovarian-type stroma inMCNs
expresses oestrogen and progesterone receptors, as well as
vimentin, smooth-muscle actin and desmin, and the stroma can
even undergo luteinization.87 Luteinized cells in noninvasive
MCNs immunolabel for tyrosine hydroxylase, calretinin and
a-inhibin.
Like PanINs and IPMNs, MCNs are graded based on
cytonuclear and architectural features as having low-, interme-
diate- or high-grade dysplasia (Figure 6). Few architectural
changes and cytonuclear abnormalities are present in low-grade
dysplasia (slight increase in nuclear size and absent mitoses)
with abundant mucin overlying basally-oriented nuclei and
strong immunolabeling for MUC5AC, the latter feature also
observed in gastric-type IPMNs (Table 3). Nuclei begin to
lose polarity and are slightly enlarged causing cellular
pseudostratification in MCNs with intermediate-grade dysplasia.
In high-grade MCNs, papillae with irregular branching can be
observed with cells showing nuclear stratification and loss
of polarity in addition to prominent nucleoli and frequent
mitoses. A particular morphologic feature that can be observed in
MCNs is an abrupt transition between high- and low-grade
dysplastic epithelium. Similarly, invasive carcinoma may arise
focally within an otherwise benign-appearing MCN. Because of
this, MCNs should be extensively, if not completely sampled for
histologic examination before diagnosing the lesion as
non-invasive.
In differentiating MCNs from other lesions, one should always
keep the characteristics of MCNs in mind, in particular the fact
that they do not communicate with the ductal system and that
they by definition contain ovarian stroma. Although the majority
of patients with an MCN are female, they do occur in males, and
so male gender cannot be used to rule out the diagnosis.Molecular alterations in MCNsMCNs have not been studied as well as PanINs and IPMNs at the
molecular level, mostly because of their lower incidence.
The expression of MUC5AC in low-grade dysplastic MCNs was
briefly mentioned before, but MUC2 can also be expressed
(restricted to goblet cells within the epithelium) in noninvasive
lesions, whereas MUC1 expression is associated with invasive
MCNs (Table 3).88 Similar to PanINs and IPMNs, MUC6
expression can be observed in the early stage of noninvasive
MCN lesions.51,88,89 An almost identical pattern of claudin
expression was found in MCNs and IPMNs, in which claudin-2
expression decreases with increasing grade of dysplasia in
contrast to claudin-4 and claudin-18 expression which increases
with increasing grade of dysplasia.90 Other genes that have
been reported to be overexpressed in MCNs include cathepsin
E (CTSE ), proto-oncogene MET (encoding hepatocyte growth
factor binding receptor), proto-oncogene MYC, PSCA, and S100
calcium binding protein P (S100P) in the epithelium, and
steroidogenic acute regulatory protein (STAR) and oestrogen
receptor 1 (ESR-1) in the ovarian-type stroma.91
Genetic alterations that have been identified in MCNs include
activating mutations in the KRAS2 gene, and inactivating SMAD4
and TP53 mutations in more advanced MCNs.92,93 2011 Elsevier Ltd. All rights reserved.
Figure 6 Histological features of different grades of dysplasia of mucinous cystic neoplasms (MCNs). (a) MCN with high-grade dysplasia (upper part) and
adjacent low-grade dysplasia (asterisk in lumen). (b) Intermediate-grade MCN with prominent ovarian-type stroma (arrows). (c) MCN with high-grade
dysplasia. Note the papillary architecture with significant nuclear atypia and loss of polarity. (d) Intermediate-grade (top cyst) and high-grade (lower cyst)
dysplasia in one MCN.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYPancreatic cyst fluid: implications for translational researchDistinguishing pancreatic cystic lesionsCysts are common in the pancreas; they have been reported
in >20% of autopsied patients and w3% in patients undergoing
abdominal imaging (CT or MRI).94,95 The increasing use and
accuracy of abdominal imaging techniques will further increase
the incidence of asymptomatic pancreatic cysts (pancreatic
incidentalomas) in the near future.96 The fact that IPMNs and
MCNs are recognized precursors to pancreatic cancer, in contrast
to other pancreatic cystic lesions, underlines the need to
accurately predict the nature of a cystic lesion so that it can be
treated appropriately (safely monitored or surgically resected).Pancreatic cyst fluid as a diagnostic modalityCyst fluid obtained through FNA during EUS has been analyzed
in several studies. CEA has been the most commonly used
biomarker for differentiating between mucinous (i.e. IPMNs and
MCNs) and nonmucinous cysts (i.e. cysts without malignant
potential such as serous cystadenomas (SCAs)). Using 800 ng/ml
as cut-off level in differentiating between mucinous and non-
mucinous lesions, a meta-analysis of 12 studies calculated
a sensitivity of 48% and specificity of 98%.97 In one of these
studies, CEA was significantly better in differentiating mucinous
from nonmucinous lesions than EUS when 192 ng/ml (sensitivity
73%, specificity 84%) was used as cut-off level.98 In a more
recent and larger series from the same institution, an improved
accuracy (sensitivity 81%, specificity 98%) was reported in
differentiating mucinous from nonmucinous cysts at an optimal
determined CEA cut-off level of 109.9 ng/ml.99 Though, theDIAGNOSTIC HISTOPATHOLOGY 18:1 25accuracy in the latter study did not differ significantly between
a CEA cut-off level of 109.9 ng/ml versus the previously
determined 192 ng/ml. In contrast with this finding is a more
recent report by Haab et al. in which at this cut-off level (192 ng/
ml) CEA alone had a sensitivity of 37% and specificity of 80% in
differentiating between mucinous and nonmucinous cysts.100
The fact that CEA levels of >450 ng/ml were reported in
lymphoepithelial cysts, which are benign lesions, reiterates the
inability to distinguish definitively between malignant and
benign cystic lesions using CEA.101,102 On the other end of the
spectrum, low levels (<5 ng/ml) of CEA strongly support
a diagnosis of SCA or pseudocyst as opposed to mucinous
neoplasms (IPMNs and MCNs).103
CEA expression in combination with 13 other proteins was
found to distinguish IPMNs from SCAs with 92% diagnostic
accuracy which suggests that CEA in combination with other
factors might be a more sensitive and specific diagnostic
modality.104 Several studies have examined the combination of
molecular and CEA analysis in distinguishing mucinous from
nonmucinous cysts and found improved diagnostic sensitivity
compared to molecular analysis by itself.105e107 Other tumour
markers besides CEA, such as CA15.3, CA19-9, CA72-4 and
CA125 have been evaluated but were found to be of lesser
diagnostic value than CEA.98,104
Expression of apomucins may also be of use. MUC5AC
expression was used to discriminate mucinous cysts from non-
mucinous cysts (78% sensitivity, 80% specificity) with
increasing sensitivity and specificity (87% and 86%, respec-
tively) when CA19-9 was added.100 In high-grade IPMNs, in
a different study, MUC2 and MUC4 levels were found 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGYsignificantly elevated and serum MUC5AC was significantly
elevated compared to low-grade lesions.108 The accuracy of
MUC1 to differentiate high-grade/invasive IPMNs from low-/
intermediate-grade IPMNs was 81% in pancreatic juice.109 These
results show that the aberrantly expressed apomucins in
precursor lesions are reflected in cyst fluid.
Another group of biomarkers in cyst fluid that warrant further
elucidation are aberrantly expressed microRNAs. One small
study found upregulated expression of miR-155 in 60% of IPMN-
associated cyst fluid specimens compared to none in control
cases.110 A recent study by Ryu et al. found that this microRNA
transcript showed a trend towards differential expression in
mucinous and nonmucinous cyst fluids.111 On the other hand,
the authors found significantly higher expression of microRNAs
miR-17-3p, miR-221, and miR-21 in the cyst fluid of mucinous
precursors versus nonmucinous precursors. Moreover, the
authors determined the diagnostic performance of the latter
microRNA (miR-21) for mucinous underlying cysts and found
a sensitivity of 80% with 76% specificity and a sensitivity of 96%
with specificity of 50%. These findings affirm microRNAs to be
helpful in differentiating between mucinous and nonmucinous
cysts based on cyst fluid analysis.
Amylase is a biomarker of limited value in cyst fluid analysis,
except that elevated amylase levels (>5-fold serum level) suggest
either a pseudocyst or a connection between the cyst and the
ductal system, thereby excluding MCNs and serous cystic
neoplasms.112
Cyst fluids have also been analyzed for KRAS2 gene muta-
tions, and the results look promising. Khalid et al. analyzed cyst
fluid for DNA quality/amount, for somatic KRAS2 mutations,
and for LOH with polymorphic microsatellite markers.113 They
found that the combination of KRAS2 gene mutations together
with LOH was highly predictive for cysts with a high-grade/
infiltrating IPMN (91% sensitivity, 93% specificity). In a larger
follow-up study, this same group confirmed these findings and
found that KRAS2 gene mutations were predictive for mucinous
cysts (versus nonmucinous cysts).105 Moreover, elevated
amounts of DNA in cyst fluid as well as the combination of
KRAS2 gene mutations with microsatellite LOH were predictive
for a high-grade and/or invasive cystic lesion. In a different
study, LOH of genomic loci (amongst which TP53 and p16
coding) and KRAS2 gene mutations were together seen in two of
four high-grade/invasive and one of 12 low-/intermediate-grade
IPMNs.114
Of interest, it has recently been shown that mutant Kras
protein can be detected using proteomic techniques. Wang et al.
successfully used the technique of “selected reaction monitoring”
by mass spectrometry to detect and quantify Ras mutations at the
protein level in cyst fluid of three IPMNs.115 DNA sequencing of
the IPMN cyst fluid in this study confirmed mutant KRAS2 genes,
thereby stressing the potential of protein based technologies to
detect DNA mutations.
The recent discovery by Wu et al. that GNAS gene mutations
are specific for IPMNs, and that these mutations can be detected
in cyst fluid, offers exciting promise for the development of
a new marker.52 The authors of this study found that 96% of
IPMNs harboured a KRAS2 and/or a GNAS gene mutation. By
contrast, none of the cyst fluids from 21 MCNs, 42 SCAs
contained GNAS mutations, thus making GNAS mutations highlyDIAGNOSTIC HISTOPATHOLOGY 18:1 26specific for IPMNs. Importantly, the GNAS mutations in the cyst
fluids were identical to those identified in matched neoplastic
epithelium from the same case, suggesting that the mutational
profile of cyst fluids accurately reflects the lesional tissues.
In addition, in IPMN-associated invasive PDACs identical GNAS
mutations were found in the invasive cancers and the matched
associated IPMN. These findings underline the usability and
representation of cyst fluid in identifying potentially underlying
disease.
In summary, the combined panel of mutations in KRAS2 and
GNAS appears to be very specific for IPMNs (with a 96%
sensitivity and 100% specificity in distinguishing IPMNs from
SCA), and the genetic analysis of cyst fluid accurately reflects the
epithelium of the cyst wall. As mutations have only been
observed in a single codon per gene involved, codon 12 of KRAS2
and codon 201 of GNAS, these genes can be assessed with as little
as 0.25 ml of aspirated cyst fluid using the ligation assay
described by Wu et al.52Conclusions
As advanced invasive PDAC is almost a universally lethal cancer,
the only hope for cure is to detect disease at an early stage.
The identification and characterization of precursors to pancre-
atic cancer are crucial. In this review we discussed several
precursor lesions, PanIN, IPMN, IOPN, ITPN and MCN and their
molecular characteristics; lesions about which knowledge is
rapidly expanding. Translation of this knowledge into reliable
early detection and treatment strategies remains a major clinical
challenge. Research developments on the use and feasibility of
cyst fluid analyses look promising and provide molecular targets
to guide clinicians on the underlying precursor lesion and stage
of disease. As the diagnostic criteria for pancreatic precursor
lesions are still challenging, it is recommended to analyze and
treat patients in a high-volume centre with an experienced
multidisciplinary team. A
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Practice points
C The identification of precursor lesions at an early, precursor,
stage is crucial to outcome.
C The accumulation of genetic alterations drives the progression
of precursor lesions into higher grades of dysplasia, and
eventually to invasive carcinoma.
C Characteristic expression of apomucin proteins in precursor
lesions can be used to differentiate between lesion types.
C The macroscopic nature of IPMNs, MCNs, IOPNs and ITPNs
makes them detectable by imaging, thus enabling clinical
follow-up of patients.
C Asymptomatic pancreatic cysts will increasingly be diagnosed
due to the increasing use and accuracy of abdominal imaging
techniques.
Research directions
C Further characterization of pancreatic precursor lesions will
enable the identification of at-risk populations for pancreatic
cancer and possibly reveal useful biomarkers.
C PanINs are microscopic lesions and therefore research into
surrogate markers for their presence is needed.
C Molecular alterations in MCNs and IPMNs are increasingly
being defined with the hope that molecular changes may also
help classify these.
C The analysis of cyst fluid is promising and research into using
cyst fluid to classify precursor lesions in the pancreas is
urgently needed.
C In pancreatic cystic lesions GNAS mutations are IPMN-specific
and combining GNAS and KRAS2 mutation analysis of cyst
fluid distinguishes IPMNs from SCAs with 96% sensitivity and
100% specificity.
MINI-SYMPOSIUM: PANCREATIC PATHOLOGY
DIAGNOSTIC HISTOPATHOLOGY 18:1 30  2011 Elsevier Ltd. All rights reserved.
